New Paper: Assessment of Medicine Quality in Emerging Markets: The changing face of inferior medicines over time.

Roger Bate

In this analysis of all our previous data, a substantial minority of medicines to treat infectious diseases in emerging markets are of suspect quality, at least 13.5% of over 10,000 samples. This is a risk to patients and threatens to accelerate drug resistance. The two main types of inferior medicines are counterfeit or falsified medicines and substandards. As efforts against fake medicines have increased over the past decade, the rate of such products has fallen in our samplings. The international community and domestic regulators must improve efforts against substandards, just as they have against falsified medicines, if quality is to improve further.
© 2014 Safe Medicines Coalition Contact Us